tirzepatide alternative titration dosing regimens of GLP‐1 receptor agonists may reduce costs and maintain weight loss efficacy - Cengiz - 2025 - Diabetes, Obesity and Metabolism Diabetes Distilled: “Twincretin” tirzepatide significantly
Description
Zepbound has a boxed warning about the potential risk of thyroid cancer
Historically, shortages prompted substitution across drug classes, with patient experience shaped largely by availability
Insurance coverage varies and is not guaranteed
MAD doses ranged from 0.2 to 0.6 mg once weekly for 6 weeks (ClinicalTrials.gov Identifier: NCT04389775)
Author contributions RG: Conceptualization, Formal Analysis, Methodology, Visualization, Writingoriginal draft
